全文获取类型
收费全文 | 37787篇 |
免费 | 2172篇 |
国内免费 | 201篇 |
专业分类
耳鼻咽喉 | 427篇 |
儿科学 | 1186篇 |
妇产科学 | 1004篇 |
基础医学 | 3805篇 |
口腔科学 | 1207篇 |
临床医学 | 3323篇 |
内科学 | 8148篇 |
皮肤病学 | 686篇 |
神经病学 | 2247篇 |
特种医学 | 1341篇 |
外国民族医学 | 4篇 |
外科学 | 6919篇 |
综合类 | 864篇 |
现状与发展 | 3篇 |
一般理论 | 27篇 |
预防医学 | 2538篇 |
眼科学 | 1364篇 |
药学 | 2903篇 |
1篇 | |
中国医学 | 269篇 |
肿瘤学 | 1894篇 |
出版年
2024年 | 39篇 |
2023年 | 413篇 |
2022年 | 1062篇 |
2021年 | 1670篇 |
2020年 | 1004篇 |
2019年 | 1275篇 |
2018年 | 1591篇 |
2017年 | 1153篇 |
2016年 | 1256篇 |
2015年 | 1357篇 |
2014年 | 1710篇 |
2013年 | 2077篇 |
2012年 | 3159篇 |
2011年 | 3038篇 |
2010年 | 1730篇 |
2009年 | 1474篇 |
2008年 | 2267篇 |
2007年 | 2333篇 |
2006年 | 2060篇 |
2005年 | 1819篇 |
2004年 | 1656篇 |
2003年 | 1382篇 |
2002年 | 1201篇 |
2001年 | 382篇 |
2000年 | 317篇 |
1999年 | 288篇 |
1998年 | 200篇 |
1997年 | 133篇 |
1996年 | 143篇 |
1995年 | 110篇 |
1994年 | 96篇 |
1993年 | 77篇 |
1992年 | 151篇 |
1991年 | 162篇 |
1990年 | 130篇 |
1989年 | 127篇 |
1988年 | 105篇 |
1987年 | 102篇 |
1986年 | 93篇 |
1985年 | 118篇 |
1984年 | 81篇 |
1983年 | 52篇 |
1982年 | 54篇 |
1981年 | 56篇 |
1980年 | 42篇 |
1979年 | 53篇 |
1978年 | 42篇 |
1975年 | 36篇 |
1974年 | 37篇 |
1973年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
992.
993.
994.
995.
Iron overload due to increased intestinal iron absorption represents an important clinical problem in patients with non-transfusion-dependent thalassemia (NTDT), particularly as they advance in age. Current models for iron metabolism in patients with beta (β)-thalassemia intermedia (TI) suggest that suppression of serum hepcidin results in increased iron absorption and release of iron from the reticuloendothelial system, leading to depletion of macrophage iron, relatively low levels of serum ferritin, and liver iron loading. The clinical consequences of iron overload in patients with NTDT are multifactorial and include endocrinopathy, bone disease, thromboembolism, pulmonary hypertension, cerebrovascular and neuronal damage, liver fibrosis or cirrhosis, and increased risk of hepatocellular carcinoma. Although serum ferritin levels correlate with liver iron concentration (LIC), they underestimate iron load in these patients compared with transfusion-dependent patients with equivalent LIC. Therefore, direct measurement of LIC is recommended with chelation therapy as indicated. 相似文献
996.
Beta-thalassemia intermedia (TI) is associated with a variety of serious clinical complications that require proactive and comprehensive management. These include skeletal deformities and osteopenia, compensatory extramedullary hematopoiesis and tumor formation, progressive splenomegaly, a hypercoagulable state resulting in thromboembolic events and pulmonary hypertension, and increased gastrointestinal iron absorption that often results in nontransfusional iron overload and liver damage. Although TI is generally considered a non-transfusion-dependent thalassemia, transfusion therapy may be an important part of the comprehensive management of this disease. This review describes the current state of the art for medical management of TI, with particular focus on the roles of splenectomy, transfusion, and iron chelation therapy. 相似文献
997.
Meuleman P Catanese MT Verhoye L Desombere I Farhoudi A Jones CT Sheahan T Grzyb K Cortese R Rice CM Leroux-Roels G Nicosia A 《Hepatology (Baltimore, Md.)》2012,55(2):364-372
Endstage liver disease caused by chronic hepatitis C virus (HCV) infection is the leading indication for liver transplantation in the Western world. However, immediate reinfection of the grafted donor liver by circulating virus is inevitable and liver disease progresses much faster than the original disease. Standard antiviral therapy is not well tolerated and usually ineffective in liver transplant patients, whereas anti-HCV immunotherapy is hampered by the extreme genetic diversity of the virus and its ability to spread by way of cell-cell contacts. We generated a human monoclonal antibody against scavenger receptor class B type I (SR-BI), monoclonal antibody (mAb)16-71, which can efficiently prevent infection of Huh-7.5 hepatoma cells and primary hepatocytes by cell-culture-derived HCV (HCVcc). Using an Huh7.5 coculture system we demonstrated that mAb16-71 interferes with direct cell-to-cell transmission of HCV. Finally we evaluated the in vivo efficacy of mAb16-71 in "human liver urokinase-type plasminogen activator, severe combined immune deficiency (uPA-SCID) mice" (chimeric mice). A 2-week anti-SR-BI therapy that was initiated 1 day before viral inoculation completely protected all chimeric mice from infection with serum-derived HCV of different genotypes. Moreover, a 9-day postexposure therapy that was initiated 3 days after viral inoculation (when viremia was already observed in the animals) suppressed the rapid viral spread observed in untreated control animals. After cessation of anti-SR-BI-specific antibody therapy, a rise of the viral load was observed. CONCLUSION: Using in vitro cell culture and human liver-chimeric mouse models, we show that a human mAb targeting the HCV coreceptor SR-BI completely prevents infection and intrahepatic spread of multiple HCV genotypes. This strategy may be an efficacious way to prevent infection of allografts following liver transplantation in chronic HCV patients, and may even hold promise for the prevention of virus rebound during or following antiviral therapy. 相似文献
998.
999.
1000.
Ibrahim Aldoss Raju Pillai Dongyun Yang Lixin Yang Shukaib Arslan Sally Mokhtari Monzr M. Al Malki Amandeep Salhotra Shilpa Shahani Haris Ali Matthew Mei Andrew Artz David Snyder Michelle Afkhami Saro Armenian Anthony Stein Guido Marcucci Stephen J. Forman Ryotaro Nakamura Vinod Pullarkat 《Blood cancer journal》2021,11(7)